EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH COMPENSATED CIRRHOSIS AND EVIDENCE OF PORTAL HYPERTENSION DUE TO PRIMARY BILIARY CHOLANGITIS (PBC)

被引：0

作者：

Levy, Cynthia ^{[1
]}

Odin, Joseph ^{[2
]}

Neff, Guy W. ^{[3
]}

Trivedi, Palak ^{[4
,5
]}

Gheorghe, Liliana-Simona ^{[6
]}

Bowlus, Christopher L. ^{[7
]}

Vierling, John M. ^{[8
,9
]}

Gulamhusein, Aliya F. ^{[10
]}

Jeong, Sook-Hyang ^{[11
]}

Xu, Emily ^{[12
]}

Yang, Ke ^{[12
]}

Choi, Yun-Jung ^{[12
]}

Watkins, Elaine ^{[12
]}

McWherter, Charles ^{[12
]}

机构：

[1] Univ Miami, Coral Gables, FL 33124 USA

[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[3] Covenant Res & Clin LLC, Sarasota, FL USA

[4] Univ Birmingham, Natl Inst Hlth Res Birmingham Biomed Res Ctr, Birmingham, W Midlands, England

[5] Univ Birmingham, Ctr Liver & Gastrointestinal Res, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England

[6] Fundeni Clin Inst, Digest Dis & Liver Transplantat Ctr, Bucharest, Romania

[7] Univ Calif Davis, Sch Med, Div Gastroenterol & Hepatol, Davis, CA 95616 USA

[8] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[9] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA

[10] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada

[11] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Seoul, South Korea

[12] Cymabay Therapeut, Newark, CA USA

来源：

HEPATOLOGY | 2021年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1269

引用

页码：762A / 763A

页数：2

共 50 条

[41] SELADELPAR IMPROVED THE LIPID PROFILE OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): RESULTS FROM PHASE 2 AND 3 CLINICAL STUDIES
Bowlus, Christopher L.
Choi, Yun-Jung
Yang, Ke
Crittenden, Barry
Kim, Dennis
McWherter, Charles
HEPATOLOGY, 2022, 76 : S1508 - S1508
[42] EFFICACY OF OBETICHOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WITH CIRRHOSIS
Vierling, J. M.
Hirschfield, G.
Jones, D. E.
Groszmann, R.
Kowdley, K. V.
Pencek, R.
Marmon, T.
MacConell, L.
GUT, 2017, 66 : A100 - A101
[43] SELADELPAR FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS: EXPERIENCE WITH 26 CIRRHOTIC PATIENTS
Mayo, Marlyn J.
Bowlus, Christopher L.
Galambos, Michael
Neff, Guy
Trivedi, Palak
Goel, Aparna
Odin, Joseph
Bacon, Bruce R.
Borg, Brian B.
Gordon, Stuart C.
Gulamhusein, Aliya
Harrison, Stephen
Levy, Cynthia
Stanca, Carmen
Vierling, John M.
Steinberg, Alexandra
Varga, Monika
Nguyen, Jaidyn
Bergheanu, Sandrin
Choi, Yun-Jung
Standen, Mary
Boudes, Pol
GASTROENTEROLOGY, 2019, 156 (06) : S1319 - S1319
[44] Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC)
Mattner, Jochen
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)
[45] Efficacy of Obeticholic Acid Treatment in Patients with Primary Biliary Cholangitis with Cirrhosis
Vierling, John M.
Hirschfield, Gideon M.
Jones, David
Groszmann, Roberto J.
Kowdley, Kris V.
Pencek, Richard
Marmon, Tonya
MacConell, Leigh
HEPATOLOGY, 2016, 64 : 187A - 187A
[46] Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Aboeldahb, Moataz
Marwan, Menna
Abdallfatah, Abdallfatah
Abosheaishaa, Hazem
Abusuliman, Mohammed
Abdelwahed, Ahmed H.
Ali, Khaled
Ismail, Abdellatif
Eldesouki, Mohamed
Hassan, Malak A.
Rahman, Haider
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1372 - S1372
[47] SELADELPAR, A PPAR-DELTA AGONIST, IMPROVES INFLAMMATORY LIPID MEDIATORS IN THE SERUM METABOLOME IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC)
Choi, Yun-Jung
Johnson, Jeff D.
Schwab, Andrew
McWherter, Charles
HEPATOLOGY, 2022, 76 : S1487 - S1487
[48] Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Mayo, Marlyn J.
Vierling, John M.
Bowlus, Christopher L.
Levy, Cynthia
Hirschfield, Gideon M.
Neff, Guy W.
Galambos, Michael R.
Gordon, Stuart C.
Borg, Brian B.
Harrison, Stephen A.
Thuluvath, Paul J.
Goel, Aparna
Shiffman, Mitchell L.
Swain, Mark G.
Jones, David E. J.
Trivedi, Palak
Kremer, Andreas E.
Aspinall, Richard J.
Sheridan, David A.
Doerffel, Yvonne
Yang, Ke
Choi, Yun-Jung
McWherter, Charles A.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 186 - 200
[49] Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Hirschfield, Gideon M.
Shiffman, Mitchell L.
Gulamhusein, Aliya
Kowdley, Kris, V
Vierling, John M.
Levy, Cynthia
Kremer, Andreas E.
Zigmond, Ehud
Andreone, Pietro
Gordon, Stuart C.
Bowlus, Christopher L.
Lawitz, Eric J.
Aspinall, Richard J.
Pratt, Daniel S.
Raikhelson, Karina
Gonzalez-Huezo, Maria S.
Heneghan, Michael A.
Jeong, Sook-Hyang
Ladron de Guevara, Alma L.
Mayo, Marlyn J.
Dalekos, George N.
Drenth, Joost P. H.
Janczewska, Ewa
Leggett, Barbara A.
Nevens, Frederik
Vargas, Victor
Zuckerman, Eli
Corpechot, Christophe
Fassio, Eduardo
Hinrichsen, Holger
Invernizzi, Pietro
Trivedi, Palak J.
Forman, Lisa
Jones, David E. J.
Ryder, Stephen D.
Swain, Mark G.
Steinberg, Alexandra
Boudes, Pol F.
Choi, Yun-Jung
McWherter, Charles A.
HEPATOLOGY, 2023, 78 (02) : 397 - 415
[50] EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE RESPONSE TRIAL: A PHASE 3 INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED STUDY
Hirschfield, Gideon M.
Bowlus, Christopher L.
Mayo, Marlyn J.
Kremer, Andreas E.
Vierling, John M.
Kowdley, Kris V.
Levy, Cynthia
Carroll, Susheela
Yang, Ke
Choi, Yun-Jung
Crittenden, Daria B.
McWherter, Charles A.
HEPATOLOGY, 2024, 79 (02) : E34 - E35

← 1 2 3 4 5 →